Sang K. Lee

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 244 publications

Rome V global epidemiology and validation survey: prevalence of disorders of gut-brain interaction and comparison with the Rome IV global epidemiology study.

Rome V global epidemiology and validation survey: prevalence of disorders of gut-brain interaction and comparison with the Rome IV global epidemiology study.

Journal: Gut
Published: June 09, 2026

Association of Mean Nocturnal Baseline Impedance and AFS EGJ Grading With AET-Defined Reflux Burden in Korean Patients.

Association of Mean Nocturnal Baseline Impedance and AFS EGJ Grading With AET-Defined Reflux Burden in Korean Patients.

Journal: Journal of gastroenterology and hepatology
Published: May 01, 2026

A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs.

A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs.

Journal: Gut and liver
Published: February 04, 2026

Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial.

Tegoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial.

Journal: Helicobacter
Published: October 14, 2025

Clinical Outcomes of Endoscopic Resection for Gastric and Duodenal Neuroendocrine Tumors.

Clinical Outcomes of Endoscopic Resection for Gastric and Duodenal Neuroendocrine Tumors.

Journal: Gut and liver
Published: August 06, 2025

Preoperative chemoradiotherapy plus pembrolizumab for esophageal squamous cell carcinoma (ACTS-29).

Preoperative chemoradiotherapy plus pembrolizumab for esophageal squamous cell carcinoma (ACTS-29).

Journal: Esophagus : official journal of the Japan Esophageal Society
Published: July 17, 2025

Corrigendum to "The long noncoding RNA LUCAT1 promotes tumorigenesis by controlling ubiquitination and stability of DNA methyltransferase 1 in esophageal squamous cell carcinoma" [Cancer Lett. (2018) 47-57].

Corrigendum to "The long noncoding RNA LUCAT1 promotes tumorigenesis by controlling ubiquitination and stability of DNA methyltransferase 1 in esophageal squamous cell carcinoma" [Cancer Lett. (2018) 47-57].

Journal: Cancer letters
Published: February 01, 2025

Comparison of Tegoprazan and Lansoprazole in Patients With Erosive Esophagitis up to 4 Weeks: A Multi-Center, Randomized, Double-Blind, Active-Comparator Phase 4 Trial.

Comparison of Tegoprazan and Lansoprazole in Patients With Erosive Esophagitis up to 4 Weeks: A Multi-Center, Randomized, Double-Blind, Active-Comparator Phase 4 Trial.

Journal: Neurogastroenterology and motility
Published: July 03, 2024

A Comprehensive Comparative Study of Potassium-Competitive Acid Blockers Is Necessary.

A Comprehensive Comparative Study of Potassium-Competitive Acid Blockers Is Necessary.

Journal: The American journal of gastroenterology
Published: May 16, 2024

Associations between Clinicopathological Characteristics and Intraoperative Opioid Requirements during Endoscopic Submucosal Dissection with Monitored Anesthesia Care: A Retrospective Study.

Associations between Clinicopathological Characteristics and Intraoperative Opioid Requirements during Endoscopic Submucosal Dissection with Monitored Anesthesia Care: A Retrospective Study.

Journal: Journal of clinical medicine
Published: May 09, 2024

Fexuprazan safeguards the esophagus from hydrochloric acid-induced damage by suppressing NLRP1/Caspase-1/GSDMD pyroptotic pathway.

Fexuprazan safeguards the esophagus from hydrochloric acid-induced damage by suppressing NLRP1/Caspase-1/GSDMD pyroptotic pathway.

Journal: Frontiers in immunology
Published: April 02, 2024

Exosomal LINC00853 promotes progression of gastric cancer via the MAP17/PDZK1/AKT signaling pathway.

Exosomal LINC00853 promotes progression of gastric cancer via the MAP17/PDZK1/AKT signaling pathway.

Journal: Non-coding RNA research
Published: January 06, 2024
Showing 1-12 of 244

Last Updated: 09/26/2026